BOULDER, CO /ACCESSWIRE/October 6, 2022/ Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, mouth and nose, and dermatological conditions, announced that he will be exhibiting at the CPHI conference in Frankfurt, Germany, November 1-3, 2022.
Sonoma Pharmaceuticals is looking to expand its presence in the European Union by adding new partners and distributors for its dermatology products, including treatments for scar management, atopic dermatitis and acne. Sonoma has also developed quality and effective products for wound care, nasal care, oral care and eye care. Interested parties can view Sonoma’s full line of safe and environmentally friendly products at booth 61G70. For more information, please visit https://sonomapharma.eu.
CPHI is the world’s leading pharma networking event. The conference is organized by Informa PLC, a leader in the business-to-business event industry, and offers visitors and exhibitors the opportunity to connect and negotiate new partnerships. CPHI welcomes pharmaceutical professionals and exhibitors from all continents.
“We look forward to showcasing our European product portfolio to pharmaceutical leaders and potential partners. We are focused on growing our European business with CE registered Class IIB medical device products used for a wide range of indications. Our Microcyn® technology has improved the quality of life for millions of people around the world and we look forward to making our safe and effective products available to Europeans,” said Amy Trombly, CEO of Sonoma Pharmaceuticals.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, animal healthcare, eye care, nasal care, oral care and skin conditions. The company’s products reduce infection, itching, pain, scarring and harmful inflammatory reactions safely and effectively. In vitro and clinical studies on hypochlorous acid (HOCl) show that it has impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itching and pain, kills pathogens and breaks down biofilm, won’t sting or irritate skin, and oxygenates cells in the treated area, aiding the body in its natural healing process . The company’s products are sold directly or through partners in 54 countries around the world and the company is actively seeking new distribution partners. The company’s main office is in Boulder, Colorado, with manufacturing operations in Latin America. European marketing and sales are based in Roermond, the Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact firstname.lastname@example.org.
Except for historical information contained in this press release, the matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about business and technological advancements and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “expect”, “believe”, and “expect”, among others. The forward-looking statements contained in this press release are subject to certain risks and uncertainties inherent in the business of doing business that could cause actual results to vary, including risks that clinical developments and regulatory guidelines may change, data scientific evidence may not be sufficient to meet regulatory standards or the receipt of required regulatory clearances or approvals, clinical results may not be replicated in real patient environments, the protection afforded by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the market available for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, the revenues will not be sufficient to meet the needs of tr business flow, fund further development, as well as uncertainties related to the COVID-19 pandemic and economic development, varied product formulations, and a multitude of regulations and marketing requirements in different countries and municipalities , and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and investor contact:
Sonoma Pharmaceuticals, Inc.
THE SOURCE: Sonoma Pharmaceuticals, Inc.
See the source version on accesswire.com: